[
    [
        {
            "time": "2018-07-31",
            "original_text": "Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment",
            "features": {
                "keywords": [
                    "GSK",
                    "BMY",
                    "Q2 Earnings",
                    "FDA",
                    "LLY",
                    "Hypoglycemia Treatment"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Pharma Stock Roundup: GSK, BMY Q2 Earnings, FDA Nod to LLY's Hypoglycemia Treatment",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-01",
            "original_text": "Senate advances bill to cut the cost of prescriptions",
            "features": {
                "keywords": [
                    "Senate",
                    "bill",
                    "cut",
                    "cost",
                    "prescriptions"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Senate advances bill to cut the cost of prescriptions",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 3,
                "Market_Scope": 10,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-08-02",
            "original_text": "EMA panel recommends approving Bayer's cancer drug Vitrakvi",
            "features": {
                "keywords": [
                    "EMA",
                    "Bayer",
                    "cancer drug",
                    "Vitrakvi"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "EMA panel recommends approving Bayer's cancer drug Vitrakvi",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2019-07-24",
            "original_text": "Eli Lilly (LLY) Stock Down 6.8% in 2019: Can Q2 Earnings Boost Performance?",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "LLY",
                    "Stock Down",
                    "Q2 Earnings"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly (LLY) Stock Down 6.8% in 2019: Can Q2 Earnings Boost Performance?",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        }
    ]
]